Aromasin Alternatives Compared
Aromasin | Ibrance | Kisqali |
|
---|
Aromasin (exemestane) | Ibrance (palbociclib) | Kisqali (ribociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Aromasin is a brand (trade) name for exemestane which is a medication that is used to treat breast cancer in postmenopausal women. It is often given to women whose cancer has progressed despite... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
|
|||||||||||||||
More about Aromasin (exemestane) | More about Ibrance (palbociclib) | More about Kisqali (ribociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Aromasin has an average rating of 4.9 out of 10 from a total of 24 ratings on Drugs.com. 27% of reviewers reported a positive effect, while 41% reported a negative effect. |
Ibrance has an average rating of 6.7 out of 10 from a total of 82 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 30% reported a negative effect. |
Kisqali has an average rating of 8.5 out of 10 from a total of 25 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: Aromasin side effects in more detail. |
See also: Ibrance side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Aromasin prices |
View all Ibrance prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
24 hours |
29 hours |
54.7 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 92 drugs are known to interact with Aromasin:
|
A total of 457 drugs are known to interact with Ibrance:
|
A total of 709 drugs are known to interact with Kisqali:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
October 21, 1999 |
February 03, 2015 |
March 13, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.